ACCELPharma (semester?), IPRO 353
MetadataShow full item record
AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.